Actinium Pharmaceuticals to Showcase ATNM-400's First-in-Human Clinical Data in Prostate Cancer and Preclinical Results in Lung Cancer Supporting Pan-Tumor Potential Today at EANM 2026

pr_newswire_finance · 2026-10-19

$ATNM

First-in-human Phase 1 presentation to feature ATNM-400 clinical data in metastatic castration-resistant prostate cancer, advancing a differentiated approach beyond PSMA Preclinical presentation to feature ATNM-400 studies in KRAS- and ALK-driven non-small cell lung cancer, exploring its...

Sector coverage: Healthcare · Biotechnology

Read the original at pr_newswire_finance ↗

Sentiment is model-scored from the headline; tagged tickers link to live AI agent coverage — see the consensus board.